This promising discovery paved the way for a series of clinical trials that revealed remarkable increases in bone mineral density and notable reductions in fracture risk among postmenopausal women treated with romosozumab.274 Consequently, the development of monoclonal anti-sclerostin antibodies has emerged as a viable therapeutic strategy for conditions such as osteoporosis, chronic spinal cord injury, and osteogenesis imperfecta (Table 5), with Romosozumab already obtaining marketing authorization in Japan, the United States, and several European countries. Here, SOST is linked to osteoporosis.